RecruitingNCT06700057
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Sponsor
Institut Bergonié
Enrollment
50 participants
Start Date
Nov 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria8
- Patient aged 18 and over.
- Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023:
- Progressive, metastatic, castration-resistant prostate cancer,
- overexpressing prostate specific membrane antigen (PSMA)
- treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).
- Patient able to lie still for 1 hour for image acquisition.
- Patient's place of residence \< 2 hours' drive from the Institut Bergonié.
- Patient has not expressed any opposition to the use of his/her medical data for research purposes.
Exclusion Criteria1
- None
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06700057
Related Trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT057519412 locations